Hepcidin levels in the Kawasaki disease patients.

<p>IVIG: intravenous immunoglobulin, pre-IVIG, 24 hours before IVIG treatment; post-IVIG, within 3 days after IVIG treatment.</p><p>*p<0.05.</p><p>Hepcidin levels in the Kawasaki disease patients.</p

Characteristics of the 851 Kawasaki disease patients.

<p>Group 1: patients with Kawasaki disease treated with high dose aspirin (>30mg/kg/day) in the acute stage. Group 2: Patients with Kawasaki disease treated without high dose aspirin (>30mg/kg/day) in the acute stage. IVIG: intravenous immunoglobulin; CAL: coronary artery lesions</p><p>Characteristics of the 851 Kawasaki disease patients.</p

Laboratory data before IVIG treatment in the Kawasaki disease patients.

<p>IVIG: intravenous immunoglobulin; CRP: C reactive peptide</p><p>Laboratory data before IVIG treatment in the Kawasaki disease patients.</p

Haplotype frequencies of the <i>ITPKC</i> gene in patients with Kawasaki disease with or without coronary artery lesion formation.

<p>Haplotype frequency less than 1% was excluded. *Significant (<i>P</i><0.05) values are in bold. CAL: coronary artery lesions.</p

<i>ITPKC</i> gene linkage disequilibrium and haplotype block structure in KD.

<p>The number on the cell is the LOD score of D'.</p

Comparison of clinical symptoms in low vs. high plasma levels of IL-31.

<p>High and low group was divided by medium value of plasma IL-31 level.</p

Increase of plasma interleukin-31 levels associated with coronary artery lesion formation in Kawasaki disease.

<p>Distribution of plasma levels of interleukin-31 (IL-31) before Intravenous immunoglobulin (IVIG) treatment (KD1), within 3 days after IVIG treatment (KD2) and at least 3 weeks after IVIG treatment (KD3). The display (2A) showed significant higher levels of IL-31 in Kawasaki disease patients with CAL formation before IVIG treatment (656.6±139.5 vs. 1373.0±422.0 pg/ml, p = 0.04) when compared with without CAL formation. After IVIG treatment, plasma levels of IL-31 showed no significant difference between patients with or without CAL (2B and 2C).</p

Demographic data of Kawasaki disease patients and the control group.

<p>Data was showed with mean and standard deviation.</p><p>KD: Kawasaki disease; FC: Fever Control; CAL: coronary artery lesion; IVIG: intravenous immunoglobulin.</p

IL-31 levels in KD patients showed no significant association with IVIG resistance.

<p>The display (3A) showed no significant difference (880.9±166.7 vs. 484.4±273.0 pg/ml, p = 0.43) in patients before IVIG treatment. Data also showed no significant difference in KD2 (1263.0±204.0 vs. 1285.0±818.9 pg/ml, p = 0.97) (3B) and KD3 (958.7±176.4 vs. 938.8±602.0 pg/ml, p = 0.97) (3C).</p

IL-31 was significantly higher in KD2 (within 3 days after IVIG treatment) when compared with KD1 (before IVIG treatment) and KD3 (at least 3 weeks after IVIG treatment).

<p>***P<0.0005. P values were tested by Paired sample t-test.</p